Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus AZLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus AZLIN.
Amoxicillin-Clavulanate vs AZLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Azlin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
1-2 grams intravenously every 4-6 hours; total daily dose up to 12 grams for serious infections.
None Documented
None Documented
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
Terminal elimination half-life is approximately 1.0–1.5 hours in adults with normal renal function; prolonged to 3–5 hours in moderate renal impairment (CrCl 10–50 mL/min) and up to 10 hours in severe renal impairment (CrCl <10 mL/min).
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal excretion of unchanged drug (approximately 60-70% via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <10%.
Category C
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic